Initial dose of three monthly intravitreal injections versus PRN intravitreal injections of bevacizumab for macular edema secondary to branch retinal vein occlusion.
OBJECTIVE
To compare visual and anatomic outcomes of intravitreal bevacizumab injections administered as needed (PRN group) and initial treatment with 3 monthly injections followed by as-needed injections (3 monthly initial dose group) in patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).


METHODS
This retrospective study included 69 and 26 patients in the PRN and 3 monthly initial dose groups, respectively. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were compared between the 2 groups 6 months after initial injection.


RESULTS
At month 6, BCVA change from baseline was -0.27 ± 0.28 (mean ± standard deviation) logMAR in the PRN group and -0.28 ± 0.20 logMAR in the 3 monthly initial dose group. Mean CRT changes were -204 ± 168 in the PRN group and -161 ± 149  μ m in the 3 monthly initial dose group at month 6. There were no statistically significant differences in BCVA or CRT changes between groups at any time point. The number of intravitreal injections over 6 months was significantly lower in the PRN group (1.8 ± 0.8 injections) than in the 3 monthly initial dose group (3.4 ± 0.5 injections; P < 0.001).


CONCLUSIONS
Our results suggest that as-needed intravitreal bevacizumab injections are more tolerable for patients with ME secondary to BRVO.
Department of Ophthalmology, College of Medicine, Seoul National University Bundang Hospital, 166 Gumiro, Bundang-gu, Seongnam, Gyeonggi-do 463-707, Republic of Korea.
Seong Joon
SJ
Ahn
Jeeyun
J
Ahn
Se Joon
SJ
Woo
Kyu Hyung
KH
Park
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D005123:Eye / Q000098:blood supply / Q000473:pathology; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab